Immune checkpoint inhibitors: The linchpins of modern immunotherapy
BA Wilky - Immunological reviews, 2019 - Wiley Online Library
Immune checkpoint inhibitors (ICIs) have revolutionized our approach to cancer treatment in
the past decade. While monoclonal antibodies to CTLA‐4 and PD‐1/PD‐L1 have produced …
the past decade. While monoclonal antibodies to CTLA‐4 and PD‐1/PD‐L1 have produced …
MiT/TFE family of transcription factors, lysosomes, and cancer
RM Perera, C Di Malta, A Ballabio - Annual review of cancer …, 2019 - annualreviews.org
Cancer cells have an increased demand for energy sources to support accelerated rates of
growth. When nutrients become limiting, cancer cells may switch to nonconventional energy …
growth. When nutrients become limiting, cancer cells may switch to nonconventional energy …
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
Background VEGF promotes an immunosuppressive microenvironment and contributes to
immune checkpoint inhibitor resistance in cancer. We aimed to assess the activity of the …
immune checkpoint inhibitor resistance in cancer. We aimed to assess the activity of the …
Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma: a review
L Paoluzzi, RG Maki - JAMA oncology, 2019 - jamanetwork.com
Importance Alveolar soft-part sarcoma (ASPS) is a rare, translocation-driven sarcoma of the
soft tissues. Alveolar soft-part sarcoma often affects young adults and is characterized by …
soft tissues. Alveolar soft-part sarcoma often affects young adults and is characterized by …
Cediranib for metastatic alveolar soft part sarcoma
Purpose Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor, for which no
effective standard systemic treatment exists for patients with unresectable disease …
effective standard systemic treatment exists for patients with unresectable disease …
[HTML][HTML] Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect
S Stacchiotti, T Negri, N Zaffaroni, E Palassini… - Annals of oncology, 2011 - Elsevier
Background The purpose of this study was to confirm sunitinib activity in alveolar soft part
sarcoma (ASPS) and to report on new insights into the molecular bases thereof. Patients …
sarcoma (ASPS) and to report on new insights into the molecular bases thereof. Patients …
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial
I Judson, JP Morden, L Kilburn, M Leahy… - The lancet …, 2019 - thelancet.com
Background Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is
unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown …
unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown …
Pleomorphic liposarcoma: clinical observations and molecular variables
MP Ghadimi, P Liu, T Peng, S Bolshakov, ED Young… - Cancer, 2011 - Wiley Online Library
BACKGROUND: Pleomorphic liposarcoma (PLS) is a rare high‐grade sarcoma that has
lipoblastic differentiation. In this study, the authors evaluated PLS natural history, patient …
lipoblastic differentiation. In this study, the authors evaluated PLS natural history, patient …
Response to sunitinib malate in advanced alveolar soft part sarcoma
S Stacchiotti, E Tamborini, A Marrari, S Brich… - Clinical Cancer …, 2009 - AACR
Purpose: Alveolar soft part sarcoma (ASPS) is a rare, chemoresistant soft tissue sarcoma.
ASPS harbors the t (17-X)(p11. 2; q25) translocation, resulting in the ASPACR1-TFE3 fusion …
ASPS harbors the t (17-X)(p11. 2; q25) translocation, resulting in the ASPACR1-TFE3 fusion …
ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97
Abstract The t (X, 17) chromosomal translocation, generating the ASPSCR1:: TFE3 fusion
oncoprotein, is the singular genetic driver of alveolar soft part sarcoma (ASPS) and some …
oncoprotein, is the singular genetic driver of alveolar soft part sarcoma (ASPS) and some …